our portfolio
Our mission is to help innovative projects grow. We invest in European Life Sciences companies focused on drug discoveries, medical devices, diagnostics and digital health. We specialize on cutting-edge ideas that have the potential to succeed on a global scale.
_ctverec.png)
ANTIVERSE
Antiverse is an AI first drug discovery company. It uses next-generation sequencing (NGS) to design functional antibodies to disease-related targets. Antiverse’s mission is to help Pharma, Biotech and Contract Research Organizations (CRO) design biologics better and faster - addressing the sectors’ most urgent unmet need.
iQure
Pharma
iQure Pharma is a US-based, global biotech company focused on the development of new therapeutics based on Polish research for neurodegenerative diseases, an indication with a high unmet medical need.
​​
iQure’s flagship compound, iQ-007, represents a first-in-class EAAT2 Positive Allosteric Modulator (PAM), designed to address toxic levels of glutamate in the synaptic cleft. Excess glutamate is a key driver of neurotoxicity and neurodegeneration in conditions such as epilepsy, including currently non-treatable Drug Resistance Epilepsy, stroke, Alzheimer’s, neuropathic pain, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
ANTIVERSE
​Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against challenging targets, including G-protein coupled receptors (GPCRs) and ion channels.
Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
vasa
therapeutics
Vasa Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the discovery and development of therapeutics that target the pathophysiology of cardiovascular aging.
The company is led by a world-class, founder-led team with an outstanding track record of successful development of numerous clinical candidates and commercial drugs spanning multiple therapeutic areas and modalities resulting in several exits values at greater than $1B (USD). Vasa has locations in California and Poland, strategically placed in vibrant academic and biotechnology innovation centers.
lam-x
LAM-X is a pioneering developer of self-sterilizing nanofiber textiles, with headquarters in Prague, Czech Republic.
​
LAM-X's nanofibers can be produced from a variety of materials, including biodegradable polymers, all while maintaining a superior efficacy in eliminating microbes without the use of heavy metals or any toxic chemicals. The company's platform technology serves as the basis for a wide range of potential products, including medical products designed to prevent infections, textiles for crop protection, and filtration systems for water and air purification.
captain t cell
Captain T Cell develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies.
​
Using a toolbox of next-generation technologies, Captain T Cell generates TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. A key technology established by the Captain T Cell team is its proprietary TCR-ALLO platform for off-the-shelf treatment of solid tumors. The TCR-ALLO platform is a versatile tool that can be expanded to a variety of cancer indications.
heartbeat.bio
HeartBeat.bio is building the worldwide first high-throughput human organoid cultivation, screening and AI-supported data analysis solution for developing first-in-class drugs to treat heart failure; faster, less expensively and with a higher probability of success in clinical trials.
The so-called Cardioid Drug Discovery Platform relies on self-assembling, highly reproducible cardiac organoids which recapitulate the human physiology and enable modeling of heart diseases in a way not achieved with other in-vitro systems. Currently, HeartBeat.bio is focused on drug-induced and different sub-types of genetic cardiomyopathies, followed by programs in diabetic cardiomyopathy, myocardial infarction, and cardiac remodeling.
Delta
Life science
Delta Life Science simplifies biosensing, the detection of biomolecules, using photonic integrated circuits.
​
Delta Life Science develops a true platform technology that can be applied for basic life-science research and in development of new multi-biomarker assays for diagnostics. In the life-science research domain it offers affordable, high-plex analysis (binding kinetics, antibody screening, concentration measurements), while in the diagnostics domain it enables rapid and quantitative detection of panels of biomarkers.
sophomer
Sophomer s.r.o. specializes in the development and production of synthetic polymers for in vitro diagnostics.
Sophomer s.r.o. is an academic startup founded by a group of people who come from both industry and academia. Their vision is to bring together two seemingly unrelated fields: immunochemistry and polymer chemistry to help anyone who uses immunoassays in their work. One of the startup's first and widely applicable products is Sophomer F10, a polymer that can replace the widely used bovine serum albumin, currently a component without which the development of immunological analytics is seemingly unimaginable.
Enzyre
The company aims to develop a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are.
​
Enzyre’s platform requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. This offers enormous benefits to patients: avoid crisis situations driven by changes in coagulation status, provide ease of mind for patients, empower patients to optimize treatment themselves, be a quick turnaround tool in the clinical setting, reduce GP consultation visits and, as a personalized diagnostic tool, offer great support in a telemedicine setting.
nanoligent
Nanoligent is a biotech company specialized in the development of cancer treatments based on unique protein conjugates.
​
Nanoligent is focused on the development of new drugs for the treatment of more than 20 different metastatic cancer types. The lead molecule is based on the targeted elimination of cancer cells overexpressing the CXCR4 receptor, a recognized biomarker for poor prognosis and therapy resistance. Nanoligent is developing a new proprietary nano-technological platform, with the potential to overcome current limitations of Antibody-Drug-Conjugates.
CasInvent Pharma
CasInvent Pharma is an early-stage drug discovery company developing a proprietary small-molecule lead compounds with anticancer properties.
​
CasInvent Pharma is developing proprietary, highly selective inhibitors of enzymes belonging to the casein kinase 1 (CK1) family, which play an important role in several disease-related processes, including the migration of leukemia cells into lymphoid organs. The small-molecule inhibitors are designed to target individual isoforms of CK1 and thereby selectively eradicate leukemic cells.
SAMpLING
HUMAN
Sampling Human is a life science technology company developing novel methods for the early detection of disease.
​
The company has developed simple and easy to perform diagnostic reagent kits for the liquid biopsy of healthy and diseased cells and a proprietary method of harnessing living cells to analyze other cells. The company engineers and manufactures accessible tools that elevate sensitivity and increase speed of assay well beyond performance limits of complex instruments such as flow cytometry.
Dracen Pharmaceuticals
Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.
​
Its goal in treating cancers is to directly shrink tumors and remodel the tumor microenvironment to make it more conducive to immuno-oncology approaches, to gain greater disease control, increase anti-tumor responses and extend patient survival in areas of unmet need.